Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.2% – Here’s Why

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares fell 8.2% on Wednesday . The stock traded as low as $7.12 and last traded at $7.0250. 68,374 shares changed hands during trading, a decline of 27% from the average session volume of 93,144 shares. The stock had previously closed at $7.65.

Analyst Ratings Changes

A number of research analysts have weighed in on GYRE shares. Wall Street Zen cut shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Gyre Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Down 8.0%

The company has a market cap of $682.21 million, a PE ratio of 704.60 and a beta of 1.97. The stock has a 50-day simple moving average of $7.97 and a 200 day simple moving average of $7.78.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $37.20 million during the quarter, compared to analysts’ expectations of $36.30 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue purchased a new stake in shares of Gyre Therapeutics in the 3rd quarter valued at $38,000. Bank of America Corp DE increased its stake in Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Gyre Therapeutics in the fourth quarter valued at approximately $77,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.